Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 1,695 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,695 shares of the company’s stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total transaction of $14,322.75. Following the completion of the sale, the chief financial officer owned 249,301 shares in the company, valued at approximately $2,106,593.45. This trade represents a 0.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, January 27th, Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40.

Relay Therapeutics Price Performance

RLAY stock traded up $0.06 on Thursday, reaching $7.71. 1,788,553 shares of the company traded hands, compared to its average volume of 2,246,533. Relay Therapeutics, Inc. has a one year low of $1.77 and a one year high of $9.04. The company has a market cap of $1.34 billion, a P/E ratio of -4.41 and a beta of 1.55. The firm has a fifty day simple moving average of $7.93 and a 200-day simple moving average of $5.93.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, sell-side analysts forecast that Relay Therapeutics, Inc. will post -2.55 EPS for the current year.

Key Headlines Impacting Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Neutral Sentiment: AAII published an explainer on why RLAY slid ~5.18%, summarizing market reaction and citing recent insider transactions as a driver. AAII Article
• Negative Sentiment: CFO Thomas Catinazzo sold 15,515 shares across Jan. 27–28 (13,820 shares at $7.62 and 1,695 at $8.45), totaling roughly $119k + $14k ≈ $120k in disclosed sales; ownership fell ~5.22% then 0.68%. SEC filing: Catinazzo SEC Filing
• Negative Sentiment: Insider Peter Rahmer sold 13,038 shares across Jan. 27–28 (11,684 at $7.62 and 1,354 at $8.45), about $89k + $11.4k ≈ $100k in sales; his holding decreased ~4.03% then 0.49%. SEC filing: Rahmer SEC Filing
• Negative Sentiment: Insider Donald A. Bergstrom sold 21,581 shares across Jan. 27–28 (18,895 at $7.62 and 2,686 at $8.45), about $144k + $22.7k ≈ $167k in sales; his stake fell ~4.28% then 0.64%. SEC filing: Bergstrom SEC Filing

Wall Street Analysts Forecast Growth

RLAY has been the topic of several recent analyst reports. Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price on the stock in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Finally, Wells Fargo & Company raised Relay Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $6.00 to $13.00 in a research report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.57.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. FNY Investment Advisers LLC increased its holdings in Relay Therapeutics by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $34,000 after acquiring an additional 5,000 shares in the last quarter. Quinn Opportunity Partners LLC bought a new stake in shares of Relay Therapeutics during the 2nd quarter valued at $35,000. May Hill Capital LLC bought a new position in Relay Therapeutics in the 2nd quarter worth $38,000. Focus Partners Advisor Solutions LLC purchased a new stake in Relay Therapeutics in the 2nd quarter worth $39,000. Finally, Quadrant Capital Group LLC increased its stake in Relay Therapeutics by 245.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 11,791 shares of the company’s stock worth $41,000 after buying an additional 8,374 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.